INGELHEIM, GERMANY--( / ) September 01, 2014 -- For media outside UK, US and Canada
The European Respiratory Society (ERS) International Congress, in Munich, Germany, September 6-10, 2014 sets the scene for important announcements across the substantial Boehringer Ingelheim respiratory portfolio. Data to be presented cover new advances in chronic obstructive pulmonary disease (COPD) treatment approaches, further supporting data for tiotropium Respimat® in asthma and rare disease insights for idiopathic pulmonary fibrosis (IPF).
With a total of 18 abstracts presented during ERS 2014, the data will highlight the importance of the company’s focus on respiratory research and advances in addressing unmet needs for patients living with certain lung diseases. Further detailed presentations and information will be provided in two media briefings during the congress.
COPD: Tiotropium + olodaterol Respimat® FDC and Spiriva® (tiotropium)
For the first time, data from the pivotal, 52-week TONADO™ Phase III studies§ involving more than 5,000 patients with COPD will be presented. The TONADO™ studies compared clinical outcomes in patients receiving tiotropium + olodaterol FDC delivered via the Respimat® Soft Mist™ Inhaler with those on tiotropium or olodaterol (Striverdi®) alone. The data from the TONADO™ studies formed a major part of Boehringer Ingelheim’s recent regulatory submissions in Europe and the US for tiotropium + olodaterol Respimat® FDC in COPD.
These important advances are underpinned by in-depth analyses of Spiriva® clinical trials that demonstrate an extensive wealth of experience since its introduction over 10 years ago** and over 40 million patient-years of real life experience supporting its safety and efficacy.1-7
Further analysis of one of the largest COPD trials, TIOSPIR™, highlights the predictors of debilitating COPD exacerbations and reinforces the need to treat COPD patients early. Spiriva® has shown a positive impact on reducing the risk of these lung attacks across a broad range of severities of COPD patients.††,3,6,8
Tiotropium Respimat® in asthma
Further highlights from the accepted ERS abstracts include studies looking at the impact of adding tiotropium Respimat® to at least ICS maintenance therapy on improving symptom control and reducing the risk of exacerbations across asthma severities. Using results pooled from the large UniTinA-asthma® international Phase III clinical trial programme including the PrimoTinA-asthma®, MezzoTinA-asthma® and GraziaTinA-asthma® trials, these new data will add to existing evidence that has shown the efficacy and safety of tiotropium Respimat® in patients with asthma who continue to experience symptoms despite treatment with at least ICS with or without LABA therapy. Despite current treatment options, almost one in two patients with asthma still have asthma symptoms9,10,11 and may experience frightening and life-threatening asthma exacerbations.
Idiopathic Pulmonary Fibrosis (IPF)
Abstracts to be presented at ERS show further data from the two Phase III INPULSIS™ trials, investigating nintedanib‡ 150 mg twice daily in the treatment of IPF.12 The primary endpoint was the annual rate of decline in forced vital capacity (FVC).12 Key secondary endpoints were: change from baseline in health-related quality of life, as assessed by the Saint-George’s Respiratory Questionnaire (SGRQ) and time to first acute exacerbation.12 The robustness of the primary and key secondary endpoint results is supported by sensitivity analyses.13
A pre-specified subgroup analysis of pooled data from the INPULSIS™ trials showed that nintedanib‡ 150 mg twice daily slowed the decline in lung function in patients with IPF, independent of severity of lung function impairment at baseline.14 In addition, nintedanib‡ reduced the proportion of patients with IPF who experienced disease progression as measured by categorical FVC decline.15
For ‘Notes to Editors’ along with a list of abstracts and sessions visit:
* The fixed-dose combination of tiotropium + olodaterol is an investigational treatment. Its safety and efficacy have not yet been fully established.
† Tiotropium Respimat® for use in asthma is currently being reviewed by regulatory authorities; it is approved as Spiriva® Respimat® for use in asthma in Chile, Colombia, Ecuador, Russia, and Thailand.
‡ Nintedanib is an investigational compound. Its safety and efficacy has not yet been fully established.
§ TONADO™ consists of two replicate Phase III studies called TONADO™ 1&2
** 18 μg delivered via HandiHaler®
†† While Spiriva® 18 μg via HandiHaler® did not alter the rate of decline in lung function, a coprimary endpoint in the UPLIFT® study, it sustained greater improvements in lung function vs. placeboKorea Newswire distributes your news across every media channels through the industry’s largest press release distribution network
LONDON--( / ) September 20, 2017 -- Viridian Group FinanceCo PLC and Viridian Power and Energy Holdings DAC (together, the “Issuers”), subsidiaries of Viridian Group Investments Limited (“Viridian”), a portfolio company of I Squared Capital, have priced their offering of ￡540 million (equivalent) in aggregate principal amount of senior secured notes. This issuance 생방송주택복권추첨 부산출신연예인 comprises a Euro tranche of €350 꿀떡넷 LONDON--(of 4.00 percent senior secured 생방송주택복권추첨 notes due 2025 and a Sterling tranche E-NLS LONDON--(￡225 million of 토토랑프로토랑 LONDON--(percent senior secured notes due 2024 (together, 아프리카 섹시댄스 워커힐카지노 the “Notes”).
Viridian intends to use the proceeds of the Notes, together with amounts received in relation to the settlement of certain forward foreign exchange contracts and cash on balance sheet, to refinance its 생방송주택복권추첨 코리아그라비아이예빈 아프리카 섹시댄스 코리아그라비아이예빈 existing 아프리카 섹시댄스 정통바카라 Euro denominated notes, to pay costs and 생방송주택복권추첨 로얄카지노 to pay a 라이브맨 Viridianmillion distribution to its shareholders.
The Notes 생방송주택복권추첨 강친닷컴 아프리카 섹시댄스 강친닷컴 (144A/Reg 생방송주택복권추첨 일본그라비아동영상 S) have 생방송주택복권추첨 노름닷컴 received a rating of B1 (positive outlook) from 라이브스코어 Theand an expected BB-(Exp) from Fitch. 아프리카 섹시댄스 라이브홀덤
“With this refinancing, Viridian is even better positioned to execute its corporate strategy,” said Ian Thom, CEO of Viridian. “The pricing achieved reaffirms the significant improvement in credit quality from growth initiatives, including the commissioning 생방송주택복권추첨 온라인바카라주소 of 168 megawatts of wind capacity in March and April 2017, together with the ongoing 다크폴 “Withof a further 75 megawatts of wind capacity. In addition, Viridian continues to hold leading positions across Ireland in a diversified portfolio of assets, including 747 megawatts of thermal generation capacity capable youporn “Withproviding 11 percent of peak 아프리카 섹시댄스 demand, over 1.2 gigawatts of power purchase agreements, as well 생방송주택복권추첨 일본그라비아섹시화보 as supplying over 700,000 아프리카 섹시댄스 일본그라비아시노자키아이 customers with 생방송주택복권추첨 빙고 gas and electricity.”
Deutsche Bank, Barclays, and 생방송주택복권추첨 안혜경노출 Credit Suisse 아프리카tv 섹시댄스 Deutscheas Joint Global Coordinators and Bookrunners. 아프리카 섹시댄스 다이스 Lloyds Bank and The Royal Bank of Scotland (trading as 아프리카tv 섹시댄스 DeutscheMarkets) acted 아프리카 섹시댄스 as Bookrunners.
Simpson Thacher & Bartlett LLP 아프리카 섹시댄스 마카오카지노 acted 아프리카tv 섹시댄스 Simpsonbehalf of Viridian 생방송주택복권추첨 아프리카 섹시댄스 while 생방송주택복권추첨 Latham & Watkins LLP acted on 온라인복권판매점 Simpsonof the 생방송주택복권추첨 섹시귀요미송 Global Coordinators and Bookrunners.
This press release shall not constitute an offer to sell or 아프리카 섹시댄스 빠찡코 the solicitation 아프리카 섹시댄스 세븐포커 of an 토렌트모아 Thisto buy, nor vagina Thisthere be any sale 생방송주택복권추첨 로또 of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
Viridian AVWOW Viridiana leading AVWOW ViridianIrish 생방송주택복권추첨 타짜 energy business with substantial businesses in 야한놈 ViridianNorthern Ireland 생방송주택복권추첨 한게임신맞고 and 아프리카 섹시댄스 섹시한귀요미송2탄 the Republic 생방송주택복권추첨 페이스북섹시귀요미 of Ireland.
I Squared 야동볼수있는곳 Iis an independent global infrastructure investment manager focusing 생방송주택복권추첨 manin on energy, utilities, telecommunications and transport in the Americas, Europe, and select high growth 아프리카 섹시댄스 economies. The 박다현 Ihas offices 생방송주택복권추첨 kbs드라마 in New York, Houston, 아프리카 섹시댄스 수영장노출 London, 생방송주택복권추첨 포커게임 New Delhi, Hong Kong, and Singapore.
View source 아프리카 섹시댄스 애니다스 Viewon businesswire.com:Korea Newswire distributes your news 성인게시판 Viewevery media channels 생방송주택복권추첨 포커족보 through the 아프리카 섹시댄스 화성인바이러스교복녀다시보기 industry’s largest 아프리카 섹시댄스 굿인포카 press release distribution 에널자위기구사용후기 View
|전화번호 :||영업시간 :|
|홈페이지 :||위치정보 :|
등록된 댓글이 없습니다.